Eli Lilly and Company and SiteOne Therapeutics, Inc. — a private biotechnology company developing treatments for pain and ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

GLP-1 drugs like Ozempic are revolutionizing diabetes care. But they’re also making users less likely to drink alcohol. That ...

Residents near the old Reilly Tar & Chemical plant on South Tibbs Avenue face a high burden of disease. EPA trying updated ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Eli Lilly (NYSE:LLY) focuses on researching, developing, and bringing to market a wide range of medicines, including ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...